The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorExoneural Network AB
About this trial
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.
Eligibility criteria
Qualifiers
Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms.
Diagnosed >6 months prior to inclusion in case of MS or stroke as well as >1 month prior to inclusion in the case of fibromyalgia.
Give written informed consent
Cognitively able to understand and follow verbal and/or written instructions
Disqualifiers
Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit
Being introduced to any new medication affecting the neuromuscular activity during the study period
Using botulinum toxin <3 month before or during the study period
Subjects <100 cm and <13 kg
Trial design
Treatments tested in this trial
- EXOPULSE Mollii Suit and EXOPULSE Suit
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov